Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Patients who received epirubicin and cyclophosphamide prior to docetaxel (EC-D) had a 21% reduction in the hazard for distant disease-free survival (DDFS) and a 17% reduction in the DFS hazard.

Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood–brain barrier and control metastatic foci. However, this problem may be ...

They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.